Humanigen Inc - ESG Rating & Company Profile powered by AI
This ESG score covers 17 United Nations SDGs including: 'Good Health & Wellbeing', 'Responsible Production & Consumption' and 'Life on Land'. This page contains a Q&A table about Humanigen Inc. Check the end of this page for potential risks for Humanigen Inc based on sector, location and size.
Humanigen Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.0, social score of 4.8 and governance score of 1.6.
2.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1353 | Vera Therapeutics Inc | 2.9 | Medium |
| 1353 | Veracyte Inc | 2.9 | Medium |
| 1393 | Humanigen Inc | 2.8 | Medium |
| 1393 | Bioventix PLC | 2.8 | Medium |
| 1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Humanigen Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Humanigen Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Humanigen Inc report the average age of the workforce?
Sign up for free to unlockDoes Humanigen Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Humanigen Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Humanigen Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Humanigen Inc offer flexible work?
Sign up for free to unlockDoes Humanigen Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Humanigen Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Humanigen Inc conduct supply chain audits?
Sign up for free to unlockDoes Humanigen Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Humanigen Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Humanigen Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Humanigen Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Humanigen Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Humanigen Inc disclose water use targets?
Sign up for free to unlockDoes Humanigen Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Humanigen Inc have a product recall in the last two years?
Sign up for free to unlockDoes Humanigen Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Humanigen Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Humanigen Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Humanigen Inc disclose parental leave metrics?
Sign up for free to unlockDoes Humanigen Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Humanigen Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Humanigen Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Humanigen Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Humanigen Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Humanigen Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Humanigen Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Humanigen Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Humanigen Inc disclose its waste policy?
Sign up for free to unlockDoes Humanigen Inc report according to TCFD requirements?
Sign up for free to unlockDoes Humanigen Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Humanigen Inc disclose energy use targets?
Sign up for free to unlockDoes Humanigen Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Humanigen Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Humanigen Inc
These potential risks are based on the size, segment and geographies of the company.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called "cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.